NCT06156774 SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project
| NCT ID | NCT06156774 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Italiana Linfomi - ETS |
| Condition | Non-hodgkin Lymphoma,B Cell |
| Study Type | OBSERVATIONAL |
| Enrollment | 130 participants |
| Start Date | 2024-04-18 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 130 participants in total. It began in 2024-04-18 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multicenter prospective observational study lead by the FIL on sarcopenia and sGA as possible predictors of efficacy and toxicity outcomes in patients undergoing CAR-T cells treatment.
Eligibility Criteria
Inclusion Criteria: * Adult patients (≥ 18 years old). * Patients with B-cell non-Hodgkin Lymphoma scheduled to received CAR-T cell product according to Agenzia Italiana del Farmaco (AIFA) indications and technical data sheet of the drug * Availability of a 18F-FDG PET/CT scan or a full dose CT scan (without contrast media) pre-treatment with CART * Written informed consent voluntarily provided Exclusion Criteria: * Patients not fulfilling the eligibility criteria
Contact & Investigator
Vittorio Ruggero Zilioli
PRINCIPAL INVESTIGATOR
ASST Grande Ospedale Metropolitano Niguarda
Frequently Asked Questions
Who can join the NCT06156774 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non-hodgkin Lymphoma,B Cell. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06156774 currently recruiting?
Yes, NCT06156774 is actively recruiting participants. Contact the research team at startup@filinf.it for enrollment information.
Where is the NCT06156774 trial being conducted?
This trial is being conducted at Alessandria, Italy, Ancona, Italy, Avellino, Italy, Aviano, Italy and 11 additional locations.
Who is sponsoring the NCT06156774 clinical trial?
NCT06156774 is sponsored by Fondazione Italiana Linfomi - ETS. The principal investigator is Vittorio Ruggero Zilioli at ASST Grande Ospedale Metropolitano Niguarda. The trial plans to enroll 130 participants.